a new subsidiary company, Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (Dana-Farber). Dr.
Dr. Lindsay A. Rosenwald, Chairman and CEO of Coronado Biosciences stated, "We are absolutely delighted to partner with one of the pioneers in this field, Dr. Wayne Marasco."Dr. Rosenwald continued, "Immuno-oncology is one of the most exciting areas in cancer drug development.Drugs that inhibit ke
Checkpoint Therapeuticsis an innovative, immuno-oncology company spun out of the laboratory of Dr. Wayne Marasco of Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, as a newly formed subsidiary of Coronado Biosciences, Inc.